chronic cough with post-COVID-19 syndrome
Conditions
Interventions
test group:Umbilical Cord Mesenchymal Stem Cell Exosomes Nebulized Inhalation
Sponsors
Huazhong University of Science and Technology Union Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1)The patients themselves voluntarily participate in this study and sign the informed consent form; (2) Informed consent form for participants below: age =18 years old or =80 years old, male or female; (3) The subject has been diagnosed with COVID-19 infection (positive nucleic acid or antigen test), and the accompanying symptoms last for more than 4 weeks; (4) Nucleic acid or antigen negative at enrollment screening; (5) The subject has persistent or intermittent cough or loss of taste and smell for =4 weeks, and no similar symptoms before COVID-19 infection; (6) The subject has never received umbilical cord mesenchymal stem cell exosomes-related treatment; (7) Patients fully understand the purpose and requirements of this clinical trial and are willing to complete the entire trial process according to the research requirements.
Exclusion criteria
Exclusion criteria: (1) age =18 years old or =80 years old; (2) Patients with the acute phase of COVID-19 infection; (3) Suspected or confirmed with serious, active bacterial, fungal, and other infections that, in the opinion of the investigator, may pose a risk when taking intervention measures; (4) Previously diagnosed with bronchial asthma, cough variant asthma, chronic cough; suffering from other lung diseases such as chronic obstructive pulmonary disease, bronchiectasis, tuberculosis, lung cancer, etc. (5) One of the following conditions during the screening period: 1)ALT OR AST> 3 times ULN; 2) eGFR <60 mL/min; (6) Patients with a history of severe allergies; (7) Patients with uncontrolled severe cardiovascular, cerebrovascular, liver, kidney, endocrine, blood system diseases, mental diseases; (8) Patients with active immunosuppression, immunodeficiency, and those who are using immunosuppressive drugs; (9) Pregnant women and lactating women; (10) Other factors that the investigator considers that the patient is not suitable for participating in the study based on the actual clinical situations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Cough valuation test(CET)questionnaire score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of symptom improvement and remission; | — |
Countries
China
Contacts
Public ContactJihui Du
Huazhong University of Science and Technology Union Shenzhen Hospital
Outcome results
None listed